Parameter
| Biomarker | VEGF/VEGFR2 (vascular endothelial growth factor/receptor 2) | Full name | Vascular endothelial growth factor A / Vascular endothelial growth factor receptor 2 | Molecular Type | Protein/nucleic acid (RNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, Prediction | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Serum (VEGF: ELISA), tumor tissue (VEGFR2: IHC, NGS) | ||
| Pathobiological Mechanisms | VEGF is a key pro-angiogenic factor. Gastric cancer cells highly secrete VEGF and VEGFR2, which activates the downstream PI3K/Akt pathway to promote tumor angiogenesis and provide nutrition for tumor growth. Patients with high expression of VEGFR2 respond well to antiangiogenic drugs such as ramucirumab | ||||
| Clinical Availability Status | Clinical use (anti-vascular therapy screening) : It is used to predict the efficacy of ramucirumab, apatinib and other anti-vascular drugs | ||||
| Notes and Dynamics | The core marker of anti-angiogenic therapy, combined with chemotherapy can improve the prognosis of patients with advanced gastric cancer. The serum VEGF level can be used to dynamically monitor the treatment response, and the resistance mechanism (such as FGFR amplification and Ang2 high expression) is the focus of current research | ||||